Evidence map›Paper›PMID 28484451›Full record

ReviewFrontiers in immunology2017

Hello from the Other Side: How Autoantibodies Circumvent the Blood-Brain Barrier in Autoimmune Encephalitis.

Maryann P Platt, Dritan Agalliu, Tyler Cutforth

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 104 citations in OpenAlex.

  1. Trial
  2. Article
  3. Choroid Plexus Abnormalities in Autoimmune Encephalitis.CNS neuroscience & therapeutics · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Maryann P PlattDepartment of Neurology, Columbia University Medical Center, New York, NY, USA.
Dritan AgalliuDepartment of Neurology, Columbia University Medical Center, New York, NY, USA.
Tyler CutforthDepartment of Neurology, Columbia University Medical Center, New York, NY, USA.
Columbia University Irving Medical Center · US

Funding

CNS angiogenesis and blood-brain barrier regulation by the Wnt inhibitor Apcdd1.R01HL116995 · NHLBI · UNIVERSITY OF CALIFORNIA-IRVINE · PI AGALLIU, DRITAN · 2013 to 2017
$1.9M
Developing a microfluidic human neurovascular unit system to investigate genetic and age-related risk factors in Alzheimer's diseaseR01AG078352 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Dritan Agalliu, Andrew Alexander Sproul · 2025 to 2026
$837k
Th17 cell-mediated CNS damage in response to recurrent S. pyogenes intranasal infectionsR56MH109987 · NIMH · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI AGALLIU, DRITAN, CUTFORTH, TYLER · 2016 to 2016
$400k
NHLBI NIH HHS R01 HL116995NIA NIH HHS R01 AG078352NIMH NIH HHS R56 MH109987
6 · The paper itself

Abstract

Antibodies against neuronal receptors and synaptic proteins are associated with autoimmune encephalitides (AE) that produce movement and psychiatric disorders. In order to exert their pathological effects on neural circuits, autoantibodies against central nervous system (CNS) targets must gain access to the brain and spinal cord by crossing the blood-brain barrier (BBB), a tightly regulated gateway formed by endothelial cells lining CNS blood vessels. To date, the pathogenic mechanisms that underlie autoantibody-triggered encephalitic syndromes are poorly understood, and how autoantibodies breach the barrier remains obscure for almost all AE syndromes. The relative importance of cellular versus humoral immune mechanisms for disease pathogenesis also remains largely unexplored. Here, we review the proposed triggers for various autoimmune encephalopathies and their animal models, as well as basic structural features of the BBB and how they differ among various CNS regions, a feature that likely underlies some regional aspects of autoimmune encephalitis pathogenesis. We then discuss the routes that antibodies and immune cells employ to enter the CNS and their implications for AE. Finally, we explore future therapeutic strategies that may either preserve or restore barrier function and thereby limit immune cell and autoantibody infiltration into the CNS. Recent mechanistic insights into CNS autoantibody entry indicate promising future directions for therapeutic intervention beyond current, short-lived therapies that eliminate circulating autoantibodies.

Indexed as

autoantibodiesautoimmune encephalitisbasal ganglia encephalitisblood–brain barrierdopamine receptorNMDA receptorpediatric autoimmune neuropsychiatric disorders associated with streptococcal infectionsSydenham’s chorea

Identifiers

PMID28484451
PMCPMC5399040
OpenAlexW2610118538

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.